329 related articles for article (PubMed ID: 35563051)
41. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
43. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
44. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.
Zent CS; LaPlant BR; Johnston PB; Call TG; Habermann TM; Micallef IN; Witzig TE
Cancer; 2010 May; 116(9):2201-7. PubMed ID: 20166206
[TBL] [Abstract][Full Text] [Related]
45. Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia.
Barrow TM; Nakjang S; Lafta F; Bilotkach K; Woodhouse L; Junge G; Tudhope SJ; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Strathdee G
Br J Cancer; 2021 Jan; 124(2):474-483. PubMed ID: 33082556
[TBL] [Abstract][Full Text] [Related]
46. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
47. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
48. Signalling to drug resistance in CLL.
Hertlein E; Byrd JC
Best Pract Res Clin Haematol; 2010 Mar; 23(1):121-31. PubMed ID: 20620976
[TBL] [Abstract][Full Text] [Related]
49. Deregulated MIR335 that targets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.
Yan J; Jiang N; Huang G; Tay JL; Lin B; Bi C; Koh GS; Li Z; Tan J; Chung TH; Lu Y; Ariffin H; Kham SK; Yeoh AE; Chng WJ
Br J Haematol; 2013 Oct; 163(1):93-103. PubMed ID: 23888996
[TBL] [Abstract][Full Text] [Related]
50. Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH; Schrappe M; Ribeiro RC; Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2004; ():118-45. PubMed ID: 15561680
[TBL] [Abstract][Full Text] [Related]
51. Myeloid-derived suppressor cells and regulatory T cells share common immunoregulatory pathways-related microRNAs that are dysregulated by acute lymphoblastic leukemia and chemotherapy.
Labib Salem M; Zidan AA; Ezz El-Din El-Naggar R; Attia Saad M; El-Shanshory M; Bakry U; Zidan M
Hum Immunol; 2021 Jan; 82(1):36-45. PubMed ID: 33162185
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
53. Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL).
Masood A; Shahshahan MA; Jazirehi AR
Curr Drug Deliv; 2012 Jan; 9(1):30-40. PubMed ID: 22023214
[TBL] [Abstract][Full Text] [Related]
54. TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype.
Franca R; Rebora P; Athanasakis E; Favretto D; Verzegnassi F; Basso G; Tommasini A; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics; 2014 Apr; 15(5):619-27. PubMed ID: 24798719
[TBL] [Abstract][Full Text] [Related]
55. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes.
Calin GA; Croce CM
Blood; 2009 Nov; 114(23):4761-70. PubMed ID: 19745066
[TBL] [Abstract][Full Text] [Related]
56. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance.
Sampath D; Plunkett W
Curr Oncol Rep; 2007 Sep; 9(5):361-7. PubMed ID: 17706164
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.
Horton TM; Whitlock JA; Lu X; O'Brien MM; Borowitz MJ; Devidas M; Raetz EA; Brown PA; Carroll WL; Hunger SP
Br J Haematol; 2019 Jul; 186(2):274-285. PubMed ID: 30957229
[TBL] [Abstract][Full Text] [Related]
58. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
59. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
Irving JA
Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
[TBL] [Abstract][Full Text] [Related]
60. Targeting the mTOR Pathway in Leukemia.
Dinner S; Platanias LC
J Cell Biochem; 2016 Aug; 117(8):1745-52. PubMed ID: 27018341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
